Start here if you're new
what it is
Hyperion DeFi is a tiny healthcare company selling an eye-device and pitching a crypto treasury story.
how it gets paid
Last filed full-year revenue in the feed was ~$57K. Trailing / multi-quarter figures elsewhere on the page (~$345K) reflect different periods— not a contradiction, just lumpy reporting.
what just happened
The latest quarter brought $317K of revenue, but EPS was still -$1.64.
At a glance
C balance sheet — red flag territory — real financial stress
55/100 earnings predictability — expect surprises
-$40.49 fy2024 eps est
$0M fy2024 rev est
op margin n/a — tiny revenue makes % meaningless
xvary composite: 15/100 — weak
What they do
Hyperion DeFi is a tiny healthcare company selling an eye-device and pitching a crypto treasury story.
The moat is weak. Hyperion has 14 employees and $57K of annual revenue. That is not a wall. It is a footnote. Your real edge here is not customer lock-in. It is whether the Optejet device or the HYPE treasury story can grow past zero.
How they make money
$57K
annual revenue
Optejet ophthalmic device
$57K
HYPE treasury strategy
$0K
Corporate development
$0K
Other
$0K
The products that matter
digital asset treasury
HYPE token treasury
~$345K trailing (feed)
the company frames HYPE as a strategic treasury asset, but the operating business underneath is still microscopic— ~$345K in one trailing window vs ~$57K in another filed period. that's a narrative asset, not a proven cash engine.
strategy, not scale
proposed reverse merger
Betaliq merger target
non-binding LOI · march 2025
this is the entire future-facing story. the LOI was announced in March 2025, but a non-binding deal is still not a deal. until it closes, you are underwriting paperwork and hope.
binary outcome
legacy diagnostics business
Legacy operations
~$345K trailing (feed)
whatever remains of the legacy business shows ~$345K in one trailing window in the feed— still too small to support the valuation on fundamentals alone.
current base
Key numbers
$57K
annual revenue
That is the full-year top line from EDGAR. It tells you the business is still microscopic.
$317K
latest quarter
The latest quarter was far bigger than the annual figure. That means revenue is lumpy, not steady.
$8M
long-term debt
Debt is about 140 times annual revenue. That gap is the whole story.
1.6
beta
A 1% market move can become a 1.6% move here. Small caps do not sit still.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $8M (21% of capital)
C — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for HYPD right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest quarter brought $317K of revenue, but EPS was still -$1.64.
Revenue rose 5% vs. prior year. Gross margin stayed at 100.0%, so the problem is scale, not product cost.
$317K
quarter revenue
-$1.64
quarter EPS
100.0%
gross margin
the number that mattered
The $317K quarter matters because it was bigger than the annual $57K figure. That tells you the business is lumpy and tiny.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is the Betaliq reverse merger never becoming a signed, closed transaction.
med
The deal stays a letter of intent
A non-binding LOI is not financing, not integration, and not closing certainty. If Betaliq falls apart, you are back to a shell with trailing revenue still in the low hundreds of thousands of dollars, not millions.
impact: the current thesis loses its center of gravity because the operating base alone does not justify a $30M market cap.
med
Dilution and selling pressure overwhelm the float
A prospectus registered 50.7M shares for potential sale. In a micro-cap, that is not background noise. It is a cap-table event.
impact: more supply can pressure the stock even if the headline story stays intact.
med
HYPE token strategy fails to matter economically
Management can talk about a strategic HYPE treasury, but filings also warn that scaling problems, technical flaws, privacy issues, or weak engagement could hurt demand and value.
impact: if the token narrative weakens, one of the few speculative supports under the stock weakens with it.
med
Volatility stops behaving like a side effect
24.18% of the float is sold short, equal to about 1.92M shares, and beta sits at 1.6. That can create violent squeezes. It can also create violent drops.
impact: price action can disconnect from business progress because the stock is thin, crowded, and event-driven.
the combined risk picture is straightforward: trailing revenue still in the ~low-$100Ks–$300Ks depending on period, 24.18% short interest, and 50.7M shares registered for sale create a stock where corporate structure matters more than operating execution.
source: institutional data · regulatory filings · risk analysis
Pay attention to
deal timeline
Does the LOI become definitive
The biggest catalyst is simple: a signed merger agreement, financing terms, and a closing path. Until then, the market is trading possibility.
dilution
Whether the 50.7M-share overhang starts hitting the tape
Micro-cap stories can survive bad optics. They struggle when new supply actually shows up.
sentiment
Short interest versus headline flow
With 1.92M shares short, positive deal news could squeeze hard. No news can leave the short case in control.
execution
Whether revenue becomes more than a rounding error
Trailing revenue in the low hundreds of thousands is not enough. You want evidence that the post-transaction company, if it closes, can report numbers that belong in millions, not footnotes.
Analyst rankings
earnings predictability
55 / 100
In human-speak, the reported numbers are not stable enough to anchor a clean forecast.
risk rank
5 / 100
Only about 5% of stocks score worse on safety. this sits in the market's danger corner.
price stability
5 / 100
A 5/100 stability score means the chart can do things fundamentals cannot explain, because fundamentals are not driving most of it.
source: institutional data
Institutional activity
institutional ownership data for HYPD is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive